INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 3 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $66,727 | -60.7% | 1,281 | -52.3% | 0.00% | -66.7% |
| Q2 2023 | $169,951 | +147683.5% | 2,684 | +26.5% | 0.01% | +50.0% |
| Q1 2023 | $115 | +150.0% | 2,121 | +146.3% | 0.00% | +100.0% |
| Q4 2022 | $46 | -100.0% | 861 | -86.3% | 0.00% | -60.0% |
| Q3 2022 | $291,000 | +28.8% | 6,263 | +57.9% | 0.01% | 0.0% |
| Q2 2022 | $226,000 | +205.4% | 3,966 | +230.8% | 0.01% | +400.0% |
| Q1 2022 | $74,000 | -28.8% | 1,199 | -39.8% | 0.00% | -50.0% |
| Q4 2021 | $104,000 | -4.6% | 1,991 | -32.2% | 0.00% | -33.3% |
| Q3 2021 | $109,000 | -18.0% | 2,937 | -9.7% | 0.00% | 0.0% |
| Q2 2021 | $133,000 | -52.3% | 3,253 | -60.5% | 0.00% | -40.0% |
| Q1 2021 | $279,000 | +220.7% | 8,241 | +199.9% | 0.01% | +66.7% |
| Q4 2020 | $87,000 | -82.2% | 2,748 | -85.6% | 0.00% | -40.0% |
| Q3 2020 | $488,000 | +154.2% | 19,044 | +154.9% | 0.01% | -37.5% |
| Q2 2020 | $192,000 | +4700.0% | 7,471 | +1394.2% | 0.01% | – |
| Q3 2019 | $4,000 | -83.3% | 500 | -73.5% | 0.00% | -100.0% |
| Q2 2019 | $24,000 | -53.8% | 1,885 | -55.4% | 0.00% | -33.3% |
| Q1 2019 | $52,000 | +300.0% | 4,225 | +265.2% | 0.00% | +200.0% |
| Q4 2018 | $13,000 | -80.6% | 1,157 | -62.4% | 0.00% | -80.0% |
| Q3 2018 | $67,000 | +3.1% | 3,078 | -24.8% | 0.01% | 0.0% |
| Q3 2017 | $65,000 | +1525.0% | 4,091 | +1103.2% | 0.01% | – |
| Q2 2017 | $4,000 | -95.4% | 340 | -94.1% | 0.00% | -100.0% |
| Q4 2016 | $87,000 | +141.7% | 5,762 | +142.1% | 0.01% | +125.0% |
| Q3 2016 | $36,000 | +227.3% | 2,380 | +712.3% | 0.00% | +300.0% |
| Q2 2016 | $11,000 | -8.3% | 293 | -31.9% | 0.00% | -50.0% |
| Q1 2016 | $12,000 | -88.7% | 430 | -78.3% | 0.00% | -88.2% |
| Q4 2015 | $106,000 | +241.9% | 1,979 | +51.1% | 0.02% | +325.0% |
| Q1 2015 | $31,000 | +675.0% | 1,310 | +555.0% | 0.00% | – |
| Q4 2014 | $4,000 | -96.8% | 200 | -97.8% | 0.00% | -100.0% |
| Q3 2014 | $125,000 | +95.3% | 9,152 | +140.5% | 0.01% | +75.0% |
| Q2 2014 | $64,000 | +481.8% | 3,806 | +541.8% | 0.01% | +700.0% |
| Q1 2014 | $11,000 | – | 593 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |